search
Back to results

Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection

Primary Purpose

Thoracic Injuries

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Gore Conformable TAG Thoracic Endoprosthesis
Sponsored by
W.L.Gore & Associates
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Thoracic Injuries focused on measuring aorta, trauma, transection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Traumatic transection of the DTA that requires repair, determined by the treating physician
  2. Traumatic aortic transection location between, but does not include, the left subclavian artery and celiac artery
  3. Endovascular repair with the GORE Conformable TAG® Device performed less than or = to 14 days after aortic injury
  4. Age greater than or equal to 18 years
  5. Proximal and distal landing zone length greater than or equal to 2.0 cm. Landing zones must be in native aorta. Landing zone may include left subclavian artery, if necessary
  6. All proximal and distal landing zone inner diameters are between 16-42 mm. Diameter assessed by flow lumen and thrombus, if present; calcium excluded
  7. Subject capable of complying with study protocol requirements, including follow-up
  8. Informed Consent Form signed by subject or legal representative

Exclusion Criteria:

  1. Differing proximal and distal neck diameters (aortic taper) outside the intended aortic diameter requirements (sizing guide) for a single endoprosthesis diameter and the inability to use devices of different diameters (in adherence to the sizing guide) to compensate for the taper
  2. Tortuous or stenotic iliac and/or femoral arteries and inability to use a conduit for vascular access
  3. Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s)
  4. Infected aorta
  5. Subject has a systemic infection and may be at increased risk of endovascular graft infection
  6. Planned coverage of left carotid or celiac arteries with the CTAG Device
  7. Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome
  8. Treatment in another drug or medical device study within 1 year of study enrollment
  9. Known history of drug abuse
  10. Pregnant female
  11. Moribund patient not expected to live 24 hours with or without operation, determined by the treating physician
  12. Injury Severity Score of 75
  13. Subject has known sensitivities or allergies to the device materials

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

GORE Conformable TAG® Thoracic Endoprosthesis

Arm Description

Outcomes

Primary Outcome Measures

All Cause Mortality
Major Device Events
Major device events requiring reintervention through 1 month study window. Possible device events include but are not limited to endoleak, migration, wire fracture, compression, erosion, extrusion, aortic dilatation, endograft infection, and aortic rupture.

Secondary Outcome Measures

Full Information

First Posted
June 8, 2009
Last Updated
July 26, 2017
Sponsor
W.L.Gore & Associates
search

1. Study Identification

Unique Protocol Identification Number
NCT00917852
Brief Title
Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection
Official Title
Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Traumatic Transection of the Descending Thoracic Aorta
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
February 28, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
W.L.Gore & Associates

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
TAG 08-02 is a prospective, multicenter, single-arm study to evaluate the use of the CTAG Device in traumatic transection of the descending thoracic aorta.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thoracic Injuries
Keywords
aorta, trauma, transection

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
51 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GORE Conformable TAG® Thoracic Endoprosthesis
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Gore Conformable TAG Thoracic Endoprosthesis
Intervention Description
Endovascular stent graft
Primary Outcome Measure Information:
Title
All Cause Mortality
Time Frame
30 days post-treatment
Title
Major Device Events
Description
Major device events requiring reintervention through 1 month study window. Possible device events include but are not limited to endoleak, migration, wire fracture, compression, erosion, extrusion, aortic dilatation, endograft infection, and aortic rupture.
Time Frame
1 month post-treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Traumatic transection of the DTA that requires repair, determined by the treating physician Traumatic aortic transection location between, but does not include, the left subclavian artery and celiac artery Endovascular repair with the GORE Conformable TAG® Device performed less than or = to 14 days after aortic injury Age greater than or equal to 18 years Proximal and distal landing zone length greater than or equal to 2.0 cm. Landing zones must be in native aorta. Landing zone may include left subclavian artery, if necessary All proximal and distal landing zone inner diameters are between 16-42 mm. Diameter assessed by flow lumen and thrombus, if present; calcium excluded Subject capable of complying with study protocol requirements, including follow-up Informed Consent Form signed by subject or legal representative Exclusion Criteria: Differing proximal and distal neck diameters (aortic taper) outside the intended aortic diameter requirements (sizing guide) for a single endoprosthesis diameter and the inability to use devices of different diameters (in adherence to the sizing guide) to compensate for the taper Tortuous or stenotic iliac and/or femoral arteries and inability to use a conduit for vascular access Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s) Infected aorta Subject has a systemic infection and may be at increased risk of endovascular graft infection Planned coverage of left carotid or celiac arteries with the CTAG Device Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome Treatment in another drug or medical device study within 1 year of study enrollment Known history of drug abuse Pregnant female Moribund patient not expected to live 24 hours with or without operation, determined by the treating physician Injury Severity Score of 75 Subject has known sensitivities or allergies to the device materials
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Farber, M.D.
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
City
Los Angeles
State/Province
California
Country
United States
City
Stanford
State/Province
California
Country
United States
City
Jacksonville
State/Province
Florida
Country
United States
City
Tampa
State/Province
Florida
Country
United States
City
Baltimore
State/Province
Maryland
Country
United States
City
Boston
State/Province
Massachusetts
Country
United States
City
Ann Arbor
State/Province
Michigan
Country
United States
City
Minneapolis
State/Province
Minnesota
Country
United States
City
Saint Louis
State/Province
Missouri
Country
United States
City
Omaha
State/Province
Nebraska
Country
United States
City
Lebanon
State/Province
New Hampshire
Country
United States
City
Lake Success
State/Province
New York
Country
United States
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Greenville
State/Province
North Carolina
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Philadelphia
State/Province
Pennsylvania
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
City
Charleston
State/Province
South Carolina
Country
United States
City
Greenville
State/Province
South Carolina
Country
United States
City
Knoxville
State/Province
Tennessee
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Temple
State/Province
Texas
Country
United States
City
Seattle
State/Province
Washington
Country
United States
City
Madison
State/Province
Wisconsin
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
30598352
Citation
Panthofer AM, Olson SL, Harris DG, Matsumura JS. Derivation and validation of thoracic sarcopenia assessment in patients undergoing thoracic endovascular aortic repair. J Vasc Surg. 2019 May;69(5):1379-1386. doi: 10.1016/j.jvs.2018.08.180. Epub 2018 Dec 28.
Results Reference
derived

Learn more about this trial

Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection

We'll reach out to this number within 24 hrs